Objective To address gaps in the data comparing non–vitamin K antagonist oral
anticoagulants (NOACs) and warfarin among patients with nonvalvular atrial fibrillation …

Objective This study incorporates the results of subgroup analyses of currently published
randomized controlled trials (RCTs) and real-world cohort studies to compare the …

Aim To assess the effectiveness and safety of rivaroxaban vs warfarin in people with non‐
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …

BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …

Background Evidence of adverse clinical outcomes for non-vitamin K antagonist oral
anticoagulant (NOACs) and warfarin in patients with atrial fibrillation (AF) and diabetes …

In patients with atrial fibrillation (AF), the safety and efficacy of nonvitamin K antagonist oral
anticoagulants (NOACs) vs warfarin according to diabetes mellitus (DM) status are not …

Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …

Aims Concomitant atrial fibrillation (AF) and diabetes mellitus (DM) increases the risk of
stroke and systemic embolic events (SEE). This meta-analysis assessed the benefit/risk …

Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated
with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …